IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 311 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,336,073 | +10.0% | 161,730 | -0.5% | 0.14% | +16.8% |
| Q2 2023 | $6,666,554 | +14.8% | 162,480 | 0.0% | 0.12% | +8.2% |
| Q1 2023 | $5,807,035 | -4.8% | 162,480 | +0.6% | 0.11% | -5.2% |
| Q4 2022 | $6,102,461 | -15.0% | 161,569 | -0.5% | 0.12% | -20.5% |
| Q3 2022 | $7,183,000 | +19.3% | 162,394 | -0.1% | 0.15% | +32.7% |
| Q2 2022 | $6,020,000 | -3.0% | 162,605 | -2.9% | 0.11% | +17.0% |
| Q1 2022 | $6,204,000 | +19.7% | 167,505 | -1.7% | 0.09% | +32.4% |
| Q4 2021 | $5,185,000 | -8.3% | 170,405 | +1.1% | 0.07% | -15.5% |
| Q3 2021 | $5,652,000 | -17.7% | 168,530 | -2.1% | 0.08% | -15.2% |
| Q2 2021 | $6,869,000 | -37.8% | 172,200 | -29.9% | 0.10% | -41.8% |
| Q1 2021 | $11,037,000 | -27.9% | 245,492 | -9.4% | 0.17% | -33.6% |
| Q4 2020 | $15,317,000 | +17.0% | 270,897 | -1.8% | 0.26% | +2.4% |
| Q3 2020 | $13,088,000 | -20.4% | 275,832 | -1.1% | 0.25% | -27.1% |
| Q2 2020 | $16,439,000 | +22.2% | 278,812 | -2.0% | 0.34% | +2.7% |
| Q1 2020 | $13,458,000 | -44.6% | 284,642 | -29.2% | 0.33% | -6.4% |
| Q4 2019 | $24,273,000 | -1.0% | 401,797 | -1.8% | 0.36% | +7.2% |
| Q3 2019 | $24,522,000 | -14.5% | 409,307 | -8.3% | 0.33% | -10.5% |
| Q2 2019 | $28,685,000 | -21.6% | 446,315 | -1.0% | 0.37% | -23.8% |
| Q1 2019 | $36,591,000 | +26.1% | 450,794 | -16.0% | 0.49% | +12.2% |
| Q4 2018 | $29,021,000 | -4.3% | 536,823 | -8.7% | 0.44% | +13.9% |
| Q3 2018 | $30,312,000 | +23.3% | 587,662 | -0.4% | 0.38% | +22.4% |
| Q2 2018 | $24,587,000 | -5.8% | 590,049 | -0.3% | 0.31% | -6.0% |
| Q1 2018 | $26,088,000 | -38.4% | 591,833 | -29.7% | 0.33% | -31.0% |
| Q4 2017 | $42,339,000 | +18.4% | 841,724 | +19.3% | 0.48% | +17.0% |
| Q3 2017 | $35,764,000 | -3.1% | 705,407 | -2.8% | 0.41% | -7.2% |
| Q2 2017 | $36,913,000 | +18.1% | 725,627 | -6.6% | 0.44% | +16.3% |
| Q1 2017 | $31,247,000 | -20.6% | 777,289 | -5.5% | 0.38% | -24.3% |
| Q4 2016 | $39,341,000 | -5.6% | 822,510 | -27.7% | 0.50% | +0.6% |
| Q3 2016 | $41,680,000 | -32.5% | 1,137,549 | -57.1% | 0.50% | +30.9% |
| Q2 2016 | $61,770,000 | +40.2% | 2,652,240 | +143.9% | 0.38% | -34.5% |
| Q1 2016 | $44,046,000 | -36.0% | 1,087,554 | -2.2% | 0.58% | -37.5% |
| Q4 2015 | $68,833,000 | – | 1,111,465 | – | 0.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |